Zoetis Inc. (ZTS) EV/Assets Ratio: 2.75x
Is Zoetis Inc.’s EV/Assets ratio high or low?
Zoetis Inc.'s EV/Assets ratio of 2.75x is 53% below its 5-year average of 5.84x, near the low end of its 5-year range (2.55x–8.84x).
The EV/Assets ratio for Zoetis Inc. (ZTS) is 2.75x as of Wednesday, June 10, 2026. It is below its 12-month average by 35.48% (4.26x).
ZTS EV/Assets Ratio Chart
ZTS Average EV/Assets Ratio Chart
ZTS Current vs Average EV/Assets Ratio Chart
ZTS EV/Assets Ratio Metrics
EV/ASSETS RATIO
2.75x
EV/ASSETS RATIO AVG TTM
4.26x
EV/ASSETS RATIO AVG 3Y
5.44x
EV/ASSETS RATIO AVG 5Y
5.84x
EV/ASSETS RATIO AVG 10Y
5.47x
EV/ASSETS RATIO AVG 15Y
4.95x
EV/ASSETS RATIO AVG 20Y
4.95x
CURRENT VS TTM AVG
-35.48%
CURRENT VS 3Y AVG
-49.42%
CURRENT VS 5Y AVG
-52.87%
CURRENT VS 10Y AVG
-49.72%
CURRENT VS 15Y AVG
-44.39%
CURRENT VS 20Y AVG
-44.39%
ZTS Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | $34.20B | 2.75x | 4.26x | 5.44x | 5.84x |
| Centene Corporation (CNC) | $31.94B | 0.33x | 0.25x | 0.39x | 0.51x |
| Agilent Technologies, Inc. (A) | $37.17B | 2.98x | 3.06x | 3.38x | 3.71x |
| Medline Inc. (MDLN) | $30.90B | 1.04x | 1.18x | 1.18x | 1.18x |
| IQVIA Holdings Inc. (IQV) | $30.60B | 1.05x | 1.56x | 1.81x | 1.98x |
| DexCom, Inc. (DXCM) | $29.24B | 4.53x | 4.23x | 5.88x | 7.47x |
| Biogen Inc. (BIIB) | $29.00B | 1.10x | 0.95x | 1.19x | 1.43x |
| Veeva Systems Inc. (VEEV) | $26.73B | 2.78x | 4.63x | 5.33x | 6.99x |
| Humana Inc. (HUM) | $43.78B | 0.96x | 0.75x | 0.88x | 1.10x |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 13.69x | 15.32x | 13.69x | 15.18x |
Zoetis Inc. EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Zoetis Inc. (ZTS)?
- The EV/Assets ratio for ZTS stock is 2.75x.
- Is Zoetis Inc.'s EV/Assets ratio high or low?
- Zoetis Inc.'s EV/Assets ratio of 2.75x is 53% below its 5-year average of 5.84x, near the low end of its 5-year range (2.55x–8.84x).
- What is the TTM average EV/Assets ratio for Zoetis Inc. (ZTS)?
- The TTM average EV/Assets ratio for ZTS stock is 4.26x.
- What is the 3Y average EV/Assets ratio for Zoetis Inc. (ZTS)?
- The 3Y average EV/Assets ratio for ZTS stock is 5.44x.
- What is the 5Y average EV/Assets ratio for Zoetis Inc. (ZTS)?
- The 5Y average EV/Assets ratio for ZTS stock is 5.84x.
- What is the 10Y average EV/Assets ratio for Zoetis Inc. (ZTS)?
- The 10Y average EV/Assets ratio for ZTS stock is 5.47x.
- What is the 15Y average EV/Assets ratio for Zoetis Inc. (ZTS)?
- The 15Y average EV/Assets ratio for ZTS stock is 4.95x.
- What is the 20Y average EV/Assets ratio for Zoetis Inc. (ZTS)?
- The 20Y average EV/Assets ratio for ZTS stock is 4.95x.
Zoetis Inc. EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-10 | 2.75x |
| 2026-06-09 | 2.77x |
| 2026-06-08 | 2.68x |
| 2026-06-05 | 2.70x |
| 2026-06-04 | 2.70x |
| 2026-06-03 | 2.64x |
| 2026-06-02 | 2.61x |
| 2026-06-01 | 2.64x |
| 2026-05-29 | 2.65x |
| 2026-05-28 | 2.66x |
| 2026-05-27 | 2.70x |
| 2026-05-26 | 2.72x |
| 2026-05-22 | 2.75x |
| 2026-05-21 | 2.71x |
| 2026-05-20 | 2.70x |
| 2026-05-19 | 2.68x |
| 2026-05-18 | 2.65x |
| 2026-05-15 | 2.55x |
| 2026-05-14 | 2.59x |
| 2026-05-13 | 2.55x |
| 2026-05-12 | 2.63x |
| 2026-05-11 | 2.62x |
| 2026-05-08 | 2.79x |
| 2026-05-07 | 2.92x |
| 2026-05-06 | 3.62x |
| 2026-05-05 | 3.66x |
| 2026-05-04 | 3.66x |
| 2026-05-01 | 3.70x |
| 2026-04-30 | 3.72x |
| 2026-04-29 | 3.69x |
| 2026-04-28 | 3.77x |
| 2026-04-27 | 3.81x |
| 2026-04-24 | 3.78x |
| 2026-04-23 | 3.76x |
| 2026-04-22 | 3.80x |
| 2026-04-21 | 3.82x |
| 2026-04-20 | 3.94x |
| 2026-04-17 | 3.93x |
| 2026-04-16 | 3.84x |
| 2026-04-15 | 3.89x |
| 2026-04-14 | 3.90x |
| 2026-04-13 | 3.87x |
| 2026-04-10 | 3.81x |
| 2026-04-09 | 3.87x |
| 2026-04-08 | 3.86x |
| 2026-04-07 | 3.78x |
| 2026-04-06 | 3.82x |
| 2026-04-02 | 3.81x |
| 2026-04-01 | 3.79x |
| 2026-03-31 | 3.82x |
| 2026-03-30 | 3.76x |
| 2026-03-27 | 3.68x |
| 2026-03-26 | 3.77x |
| 2026-03-25 | 3.77x |
| 2026-03-24 | 3.75x |
| 2026-03-23 | 3.73x |
| 2026-03-20 | 3.74x |
| 2026-03-19 | 3.75x |
| 2026-03-18 | 3.79x |
| 2026-03-17 | 3.91x |
| 2026-03-16 | 3.81x |
| 2026-03-13 | 3.74x |
| 2026-03-12 | 3.74x |
| 2026-03-11 | 3.86x |
| 2026-03-10 | 3.88x |
| 2026-03-09 | 3.93x |
| 2026-03-06 | 3.91x |
| 2026-03-05 | 3.93x |
| 2026-03-04 | 4.04x |
| 2026-03-03 | 4.04x |
| 2026-03-02 | 4.12x |
| 2026-02-27 | 4.18x |
| 2026-02-26 | 4.14x |
| 2026-02-25 | 4.12x |
| 2026-02-24 | 4.11x |
| 2026-02-23 | 4.03x |
| 2026-02-20 | 4.12x |
| 2026-02-19 | 4.07x |
| 2026-02-18 | 4.13x |
| 2026-02-17 | 4.02x |
| 2026-02-13 | 4.06x |
| 2026-02-12 | 4.03x |
| 2026-02-11 | 4.10x |
| 2026-02-10 | 4.09x |
| 2026-02-09 | 4.06x |
| 2026-02-06 | 4.07x |
| 2026-02-05 | 4.05x |
| 2026-02-04 | 4.05x |
| 2026-02-03 | 3.92x |
| 2026-02-02 | 4.00x |
| 2026-01-30 | 3.99x |
| 2026-01-29 | 3.90x |
| 2026-01-28 | 3.91x |
| 2026-01-27 | 4.00x |
| 2026-01-26 | 3.97x |
| 2026-01-23 | 3.97x |
| 2026-01-22 | 3.98x |
| 2026-01-21 | 4.00x |
| 2026-01-20 | 3.95x |
| 2026-01-16 | 3.99x |
| 2026-01-15 | 4.01x |
| 2026-01-14 | 4.02x |
| 2026-01-13 | 3.99x |
| 2026-01-12 | 4.01x |
| 2026-01-09 | 4.06x |
| 2026-01-08 | 4.05x |
| 2026-01-07 | 4.02x |
| 2026-01-06 | 4.12x |
| 2026-01-05 | 4.12x |
| 2026-01-02 | 4.02x |
| 2025-12-31 | 4.02x |
| 2025-12-30 | 4.04x |
| 2025-12-29 | 4.03x |
| 2025-12-26 | 4.03x |
| 2025-12-24 | 4.01x |
| 2025-12-23 | 3.95x |
| 2025-12-22 | 3.96x |
| 2025-12-19 | 3.92x |
| 2025-12-18 | 3.93x |
| 2025-12-17 | 3.92x |
| 2025-12-16 | 3.95x |
| 2025-12-15 | 3.88x |
| 2025-12-12 | 3.81x |
| 2025-12-11 | 3.78x |
| 2025-12-10 | 3.79x |
| 2025-12-09 | 3.73x |
| 2025-12-08 | 3.80x |
| 2025-12-05 | 3.81x |
| 2025-12-04 | 3.86x |
| 2025-12-03 | 3.93x |
| 2025-12-02 | 3.98x |
| 2025-12-01 | 4.06x |
| 2025-11-28 | 4.09x |
| 2025-11-26 | 4.08x |
| 2025-11-25 | 4.08x |
| 2025-11-24 | 3.93x |
| 2025-11-21 | 3.91x |
| 2025-11-20 | 3.73x |
| 2025-11-19 | 3.77x |
| 2025-11-18 | 3.80x |
| 2025-11-17 | 3.82x |
| 2025-11-14 | 3.87x |
| 2025-11-13 | 3.88x |
| 2025-11-12 | 3.89x |
| 2025-11-11 | 3.85x |
| 2025-11-10 | 3.84x |
| 2025-11-07 | 3.86x |
| 2025-11-06 | 3.84x |
| 2025-11-05 | 3.87x |
| 2025-11-04 | 3.98x |
| 2025-11-03 | 4.81x |
| 2025-10-31 | 4.80x |
| 2025-10-30 | 4.80x |
| 2025-10-29 | 4.80x |
| 2025-10-28 | 4.84x |
| 2025-10-27 | 4.91x |
| 2025-10-24 | 4.86x |
| 2025-10-23 | 4.87x |
| 2025-10-22 | 4.90x |
| 2025-10-21 | 4.86x |
| 2025-10-20 | 4.83x |
| 2025-10-17 | 4.80x |
| 2025-10-16 | 4.78x |
| 2025-10-15 | 4.74x |
| 2025-10-14 | 4.78x |
| 2025-10-13 | 4.75x |
| 2025-10-10 | 4.71x |
| 2025-10-09 | 4.78x |
| 2025-10-08 | 4.78x |
| 2025-10-07 | 4.76x |
| 2025-10-06 | 4.84x |
| 2025-10-03 | 4.88x |
| 2025-10-02 | 4.88x |
| 2025-10-01 | 4.89x |
| 2025-09-30 | 4.87x |
| 2025-09-29 | 4.77x |
| 2025-09-26 | 4.79x |
| 2025-09-25 | 4.71x |
| 2025-09-24 | 4.73x |
| 2025-09-23 | 4.76x |
| 2025-09-22 | 4.82x |
| 2025-09-19 | 4.86x |
| 2025-09-18 | 4.90x |
| 2025-09-17 | 4.89x |
| 2025-09-16 | 4.91x |
| 2025-09-15 | 4.87x |
| 2025-09-12 | 4.93x |
| 2025-09-11 | 5.00x |
| 2025-09-10 | 4.97x |
| 2025-09-09 | 4.98x |
| 2025-09-08 | 5.04x |
| 2025-09-05 | 5.09x |
| 2025-09-04 | 5.08x |
| 2025-09-03 | 5.06x |
| 2025-09-02 | 5.07x |
| 2025-08-29 | 5.18x |
| 2025-08-28 | 5.13x |
| 2025-08-27 | 5.15x |
| 2025-08-26 | 5.13x |
| 2025-08-25 | 5.14x |
| 2025-08-22 | 5.19x |
| 2025-08-21 | 5.16x |
| 2025-08-20 | 5.19x |
| 2025-08-19 | 5.16x |
| 2025-08-18 | 5.06x |
| 2025-08-15 | 5.11x |
| 2025-08-14 | 5.08x |
| 2025-08-13 | 5.06x |
| 2025-08-12 | 4.98x |
| 2025-08-11 | 4.96x |
| 2025-08-08 | 4.90x |
| 2025-08-07 | 4.93x |
| 2025-08-06 | 4.88x |
| 2025-08-05 | 4.87x |
| 2025-08-04 | 5.18x |
| 2025-08-01 | 5.04x |
| 2025-07-31 | 4.99x |
| 2025-07-30 | 5.09x |
| 2025-07-29 | 5.16x |
| 2025-07-28 | 5.15x |
| 2025-07-25 | 5.19x |
| 2025-07-24 | 5.21x |
| 2025-07-23 | 5.23x |
| 2025-07-22 | 5.16x |
| 2025-07-21 | 5.04x |
| 2025-07-18 | 5.08x |
| 2025-07-17 | 5.12x |
| 2025-07-16 | 5.17x |
| 2025-07-15 | 5.21x |
| 2025-07-14 | 5.30x |
| 2025-07-11 | 5.28x |
| 2025-07-10 | 5.40x |
| 2025-07-09 | 5.39x |
| 2025-07-08 | 5.37x |
| 2025-07-07 | 5.35x |
| 2025-07-03 | 5.42x |
| 2025-07-02 | 5.41x |
| 2025-07-01 | 5.42x |
| 2025-06-30 | 5.31x |
| 2025-06-27 | 5.32x |
| 2025-06-26 | 5.31x |
| 2025-06-25 | 5.35x |
| 2025-06-24 | 5.37x |
| 2025-06-23 | 5.36x |
| 2025-06-20 | 5.35x |
| 2025-06-18 | 5.28x |
| 2025-06-17 | 5.49x |
| 2025-06-16 | 5.58x |
| 2025-06-13 | 5.58x |
| 2025-06-12 | 5.72x |
| 2025-06-11 | 5.64x |
| 2025-06-10 | 5.67x |
| 2025-06-09 | 5.59x |
| 2025-06-06 | 5.76x |
| 2025-06-05 | 5.71x |
| 2025-06-04 | 5.71x |
| 2025-06-03 | 5.77x |
| 2025-06-02 | 5.74x |
| 2025-05-30 | 5.72x |
| 2025-05-29 | 5.67x |
Showing the most recent 260 of 3,359 data points. The chart above shows the full history.
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck